A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer

NCT03258398 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Microsatellite Stable Relapsed or Refractory Colorectal Cancer

Interventions

DRUG: eFT508
DRUG: Avelumab

Sponsor

Effector Therapeutics

Collaborators

[object Object]
[object Object]